SBOT, LLC

09/04/2012

The first dog entered in the canine study for ADXS vaccine is also entered in a contest. Show some love:-)

In March of 2012, Sasha was diagnosed with bone cancer,and her right arm was amputated. In May, Sasha was the first dog to be enrolled in The Mason Bone Cancer Study and receive a very special vaccine in July. The purpose of this study is to see if the vaccine can elicit anti-tumor immunity and pr...

08/02/2012

Canine studies moving forward for Advaxis

Advaxis, Inc., , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first two dogs have been dosed in

07/24/2012

STEM looking good in preliminary news

StemCells Inc. hopes a clinical trial of its proprietary stem cells in rodents will lead to a clinical trial with Alzheimer's patients.

07/13/2012

I know I've been quiet but we're still here! Working on several projects have kept me busy but always looking for great investments! Here's a good example why:

In 1992, the 400th richest person in America made $24 million.In 2007, the 400th richest person in America made $138 million (or $87 million, inflation-adjusted). Now, that almost certainly wasn't the ...

06/13/2012

more news on Advaxis... granted preclinical but VERY positive. The pipeline is deep and the phase II studies are progressing well

Advaxis, Inc., , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical ... | June 13, 2012

06/05/2012

Nice report on Advaxis from Zack's, includes data presented at ASCO conference. Still love this diamond in the rough. Check out first patient on chart with large tumor mass count, total remission on ADXS alone, no cisplatin. VERY postive! https://viewer.zoho.com/docs/bnTbA

05/15/2012

For those who have asked, partnership is passing on the Facebook IPO... high valuation. Let the excitement from the IPO settle and then review is our take on it. Good luck to all!

05/15/2012

Advaxis has been quietly putting things in order... this could be a high flyer with the results to be discussed at the ASCO conference in 3 weeks. Partnership retains its long position on ADXS

Advaxis, Inc., , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has retired approximately $4.5 million in aggregate convertible debt due on May 12, 2012, October 31, 2012, and January 9, 2013.

05/01/2012

more on Advaxis this morning

Advaxis, Inc , (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that an abstract has been selected for poster & block symposium.

04/30/2012

"In light of some favorable recent news from Advaxis, we pay particular attention to cancer immunotherapy vaccination, an area that is rapidly drawing interest."

The one place to find the companies, technologies and ideas shaping the future of healthcare

04/12/2012

Advaxis wins industry award!

Advaxis, Inc., , a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been selected as the Best Therapeutic Vaccine at the 5th Annual Vaccine Industry Excellence Awards for its ADXS-HPV construct.

03/22/2012

As an investor in the segment.. in my opinion this is a good thing. Of course big pharma is not in favor... they will no longer be able to steal small bio's with groundbreaking treatments starved for cash for just pennies on the dollar of potential value. As well as the most important reason, bring hope to the patients of rare diseases

NEW YORK, NY--(Marketwire - Mar 22, 2012) - In recent years, smaller biotechnology companies have received less funding from venture capitalists than in years past. According to the Biotechnology Industry Organization (BIO), roughly 61 percent of venture capitalists cite the FDA's challenging approv...